Every 10-Q that Stepan Co. (SCL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SCL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCL filings page.
Stepan Company reported stronger Q2 2026 results, with net sales of $ 684,109 (in thousands) up from $ 594,689, gross profit of $ 99,982, operating income of $ 37,210 and net income of $ 22,911, or $ 1.00 per basic and diluted share.
For the first six months of 2026, net sales were $ 1,288,618 (in thousands) versus $ 1,187,944, but a business restructuring charge of $ 70,545 and higher unallocated corporate expenses drove an operating loss of $ ( 12,412 ) and a net loss of $ ( 18,495 ), compared with net income of $ 31,052 a year earlier.
Operating cash flow for the six months was $ 25,298 (in thousands), capital expenditures were $ 54,294, cash and cash equivalents were $ 113,705, and total debt including current maturities was $ 647,571 at June 30, 2026. The company accrued environmental and legal reserves of $ 19,619 within an estimated loss range up to $ 46,483.
Stepan Company reported a sharp swing to a loss in Q1 2026, driven by a major restructuring under Project Catalyst. Net sales rose slightly to $604.5 million, but the company recorded a net loss of $41.4 million, or $(1.81) per diluted share, versus earnings of $0.86 a year earlier.
The loss reflects a $65.4 million pre-tax business restructuring charge tied to shutting down the Fieldsboro, New Jersey site and decommissioning assets at the Millsdale, Illinois and Stalybridge, U.K. facilities. Adjusted net income was $10.3 million, or $0.45 per diluted share, down from $0.84.
Surfactants remained the largest segment, generating $453.7 million of net sales but lower operating income, while Polymers earned slightly more despite an 11% sales decline. Specialty Products grew sales 24% but saw lower profit due to product mix and higher raw material costs. Operating cash flow improved to $16.9 million, and Stepan ended the quarter with $140.8 million in cash and $651.7 million of total debt.
Stepan Company (SCL) filed its quarterly report, showing mixed Q3 results. Net sales rose to $590,284,000, but net income declined to $10,839,000, with diluted EPS of $0.47. Operating income was $21,794,000 as higher interest expense weighed on results.
For the nine months, net sales reached $1,778,228,000 while net income was $41,891,000 with diluted EPS of $1.83. Cash and cash equivalents were $118,537,000, and total debt was $655,472,000. Operating cash flow was $87,891,000 and capital expenditures were $87,896,000.
By segment in Q3, Surfactants delivered $15,718,000 operating income, Polymers $14,104,000 and Specialty Products $9,634,000, offset by unallocated corporate expenses. Accumulated other comprehensive loss improved to $(138,608,000). The company recorded environmental and legal accruals of $19,406,000 and paid a $1,126,000 USEPA civil penalty, recovering $500,000. Assets held for sale include SPQI’s Philippines manufacturing assets with $8,476,000 of assets and $4,571,000 of liabilities, with closing planned in the fourth quarter of 2025.
Stepan Company (NYSE: SCL) filed its Q2-25 Form 10-Q. Net sales rose 6.9% YoY to $594.7 million, driven by 8.3% growth in Surfactants and 1.9% in Polymers; Specialty Products advanced 21.5%. Gross profit improved 3.4% to $71.9 million, but operating income slipped 3.8% to $18.0 million as selling and R&D costs increased 6.0%. Higher interest expense (-106% YoY) cut pre-tax earnings 20% to $13.8 million; however, a sharply lower effective tax rate (17.7% vs. 44.7%) lifted net income 19% to $11.3 million, or $0.50 diluted EPS.
For the six-month period, revenue gained 7.2% to $1.19 billion and operating income rose 19% to $46.3 million. Net income reached $31.1 million (+32.6%), translating to $1.36 EPS.
Segment detail (Q2): Polymers profit jumped 26% to $17.2 million on higher volume and price/mix, offsetting declines in Surfactants (-22%) and Specialty Products (-28%). Corporate expense fell 8%.
Balance sheet: Cash fell to $88.9 million (-$10.8 million YTD) as operating cash flow weakened to $18.1 million from $71.1 million. Capex remained elevated at $58.3 million. Total debt increased 5.3% to $658 million after issuing $75 million of 6.17% senior notes; net leverage stands near 1.1× EBITDA. Equity improved to $1.24 billion, aided by a $57 million favorable FX translation adjustment that reduced AOCI.
Other highlights: • Assets of the Philippine surfactant plant ($8.7 million) classified as held for sale.
• Environmental liabilities accrued at $19.5 million (low end of $19.5–$44.9 million range).
• New U.S. tax act (enacted 7-4-25) not yet reflected; management expects no material 2025 impact.
Outlook: Management continues to invest in capacity (capex $58 million YTD) while navigating higher financing costs and mixed segment margins. Sale of the Philippine site and working-capital normalization are expected to support liquidity in 2H-25.